Tirzepatide for beginners

The short version

Tirzepatide is a peptide, a short chain of amino acids, made in a lab. It acts on the docking points for two hormones your gut releases after a meal: GIP and GLP-1. It was the first approved medicine to act on both.

Tirzepatide is the active ingredient in FDA-approved prescription injections. They are approved for particular uses, including type 2 diabetes, long-term weight management in some adults, and a breathing problem during sleep in some adults with obesity.

Compounded tirzepatide is made to order by a pharmacy. It is not FDA-approved, and an FDA-approved version exists. Both need a prescription. They are not the same product, and only the approved one has been reviewed by the FDA.

How is tirzepatide different from semaglutide?

Both are peptides built around gut hormones called incretins. An incretin is a hormone the gut releases after eating that helps the pancreas release insulin.

Semaglutide acts on one incretin receptor, the docking point for GLP-1. Tirzepatide acts on two: the GLP-1 receptor and the receptor for GIP (glucose-dependent insulinotropic polypeptide). Lab studies found it works on the GIP receptor more strongly.

It is a chain of thirty-nine amino acids based on the natural GIP sequence. A fatty side chain lets it cling to a common blood protein, keeping it in the body for about five days.

What does it do in the body?

Researchers describe what follows from acting on both receptors:

• The pancreas releases more insulin, mainly when blood sugar is high.
• The pancreas releases less glucagon, a hormone that raises blood sugar.
• The stomach empties more slowly.
• Signals reach parts of the brain involved in hunger and fullness.

That is how the molecule works, not a promise about what it will do for you.

What is the approved medicine for?

The FDA first approved tirzepatide in May 2022, and its approved uses have grown since. In broad terms, they include:

• helping control blood sugar in type 2 diabetes, alongside diet and exercise, in adults and, since December 2025, children aged 10 and older;
• lowering the risk of serious heart problems in some adults with type 2 diabetes who are at high risk;
• long-term weight management in certain adults, approved in November 2023;
• moderate to severe obstructive sleep apnea, where breathing keeps stopping during sleep, in adults with obesity.

The current label is the authority, and it changes as new uses are approved.

What is compounded tirzepatide, and where does it stand now?

Compounding is when a pharmacy makes a medicine to order. A compounded medicine is not FDA-approved: the FDA does not check that it works, that it is safe, or that it was made well.

Tirzepatide injections went on the FDA's national shortage list in December 2022. While a medicine is officially short, pharmacies may copy it, and many did.

The FDA said the shortage was over on 2 October 2024, looked again because of a court case, and confirmed it on 19 December 2024. The extra room allowed during the shortage ended on 18 February 2025 for ordinary compounding pharmacies and on 19 March 2025 for larger outsourcing facilities. A court challenge to the FDA's decision failed, including on appeal in August 2026.

What that means now:

• Since the shortages ended, federal law limits when a pharmacy may compound essentially a copy of an approved drug, and a lower price is not a reason the FDA accepts.
• Compounded versions are not FDA-approved, and FDA-approved versions exist.
• A telehealth company must not call a compounded version a generic, say it is the same as the approved drug, or say the FDA approved it.

Fakes are a problem too: the FDA has found vials whose labels name a pharmacy that does not exist.

What does a prescription route look like?

1. A clinician licensed in your state reviews your health history, by video or through a form they can follow up on.
2. They decide whether tirzepatide fits you. Not everyone qualifies.
3. If it does, the prescription goes to a state-licensed pharmacy, which decides separately whether it can lawfully prepare it. A prescription does not guarantee that a pharmacy will fill it.

The FDA's plain advice is to get a prescription and use a state-licensed pharmacy, which you can check through its BeSafeRx page. Questions to ask any provider has a longer checklist.

What does the research show, and what does it not?

Tirzepatide has been tested in two large trial programmes: SURPASS, in type 2 diabetes, and SURMOUNT, in obesity. SURPASS-2 compared it with semaglutide in type 2 diabetes. SURMOUNT-1 compared it with a placebo, a dummy treatment, in adults with obesity but no diabetes. SURMOUNT-5 compared it with semaglutide in adults with obesity. Results like these underpin its approvals.

What the research leaves open:

• It studied the approved product. Its findings say nothing reliable about a compounded or research-labelled vial.
• Much of the strongest evidence comes from trials the maker paid for. That is normal for a new drug, but worth knowing.
• Stopping matters. Weight tended to return after people stopped in trial extensions.
• Long-term questions remain, including how much of the weight lost is muscle.

What side effects and cautions are known?

The most common side effects are nausea, vomiting, diarrhoea, constipation and less appetite, mostly while the amount is being raised. Other cautions a clinician checks:

• A boxed warning based on thyroid tumours in rodents. It has not been shown in people, but the label says tirzepatide is not for anyone with a personal or family history of medullary thyroid cancer or MEN 2.
• Gallbladder problems, more common than with comparison treatments in pooled trials.
• Pancreatitis, an inflamed pancreas, which is watched for on the label.
• Low blood sugar, mainly when taken with insulin or certain other diabetes medicines.
• Pregnancy. The label says to stop as soon as a pregnancy is known. That is different from semaglutide's label.

By the end of May 2026 the FDA had more than 730 problem reports for compounded tirzepatide, though a report does not prove the medicine caused the problem.

Asking a licensed clinician about tirzepatide

Whether tirzepatide could fit you is a question for a licensed clinician. Promise Peptides is a U.S. telehealth platform. Promise prescribes peptides now through licensed U.S. providers. A licensed U.S. provider reviews every request and your health history, then decides whether to prescribe. Not everyone qualifies, and the answer can be no. Prescribed medicines are prepared by licensed U.S. compounding pharmacies. Each pharmacy separately decides whether it can lawfully prepare a prescription; a prescription does not guarantee it will be filled. Compounded medicines are not FDA-approved, and an FDA-approved version of tirzepatide exists. How Neo is paid for sets out the rest. U.S. patients only. Availability varies by state and by treatment. Promise is LegitScript-certified. That certification is not FDA approval.

Visit Promise Peptides for tirzepatide

Neo may earn money when readers become Promise patients.

Sources

1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept (Mol Metab, 2018)PubMed
2. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)PubMed
3. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (N Engl J Med, 2021)PubMed
4. Tirzepatide Once Weekly for the Treatment of Obesity (N Engl J Med, 2022)PubMed
5. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (N Engl J Med, 2025)PubMed
6. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis (Front Endocrinol, 2023)PubMed
7. Tirzepatide (StatPearls)NCBI Bookshelf, U.S. National Library of Medicine
8. Drugs@FDA: FDA-Approved DrugsU.S. Food and Drug Administration
9. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizeU.S. Food and Drug Administration
10. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration
11. FDA to Telehealth Companies: What to Know When Promoting Compounded DrugsU.S. Food and Drug Administration
12. Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration
13. BeSafeRx: Locate a State-Licensed Online PharmacyU.S. Food and Drug Administration